Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Secukinumab (AIN457) showed superiority over Enbrel® in clearing skin, according to pivotal Novartis Phase III psoriasis results at EADV
Secukinumab shines in small MS trial
Axoskeletal proteins prevent oligodendrocyte from toxic injury by upregulating survival, proliferation, and differentiation in vitro.
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
A Novel MicroRNA-132-Surtuin-1 Axis Underlies Aberrant B-cell Cytokine Regulation in Patients with Relapsing-Remitting Multiple Sclerosis.
Purkinje cell pathology and loss in multiple sclerosis cerebellum.
Protective effect of tanreqing injection on axon myelin damage in the brain of mouse model for experimental autoimmune encephalomyelitis.
Overview of the biology of type I interferons.
Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis.
Increased promoter methylation of the immune regulatory gene SHP-1 in leukocytes of multiple sclerosis subjects.
Multiple Sclerosis and Venous Abnormalities: Medicine in the Age of Social Media.
Uncovering Cryptic Glycan Markers in Multiple Sclerosis (MS) and Experimental Autoimmune Encephalomyelitis (EAE).
RORγt-specific transcriptional interactomic inhibition suppresses autoimmunity associated with TH17 cells.
Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient.
Heat shock protein 27 in multiple sclerosis relapses.
Pregnancy in multiple sclerosis: a questionnaire study.
Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre.
Enhanced myelination in autoimmunity and in normal development induced by glatiramer acetate.
Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging.
Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study.
Venocentric Lesions: An MRI Marker of MS?
Comparison of DNA-Hydrolyzing Antibodies from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis.
Our history
Placebo power.
Quality of Life Assessment in Patients with Multiple Sclerosis Receiving Interferon Beta-1a: A Comparative Longitudinal Study of Avonex and Its Biosimilar CinnoVex.

Pages